Athira Pharma, Inc. Stock Price, News & Analysis

Athira Pharma, Inc. (NASDAQ: ATHA) revealed significant findings from its Phase 2 ACT-AD trial and new preclinical data during the AAN 2023 Annual Meeting. A post hoc analysis showed that patients treated with fosgonimeton exhibited a notable improvement in Mini-Mental State Examination (MMSE) scores (+1.6 pts, p=0.0350) and a decrease in neurodegeneration biomarkers. Additionally, preclinical data on ATH-1105 indicated prolonged survival and improved motor function in ALS mouse models. Athira continues to advance its exploration of the HGF/MET neurotrophic system as a potential treatment for neurodegenerative diseases, positioning ATHA for future clinical evaluation.

Athira Pharma, a biopharmaceutical company, announced upcoming presentations at the American Academy of Neurology (AAN) Annual Meeting, scheduled for April 22-27, 2023, in Boston. The presentations will feature new clinical data from the completed Phase 2 ACT-AD trial of fosgonimeton for Alzheimer's disease, showcasing improvements in cognitive measures and plasma biomarkers. Additionally, preclinical research will support the therapeutic potential of fosgonimeton and ATH-1105 in neurodegenerative conditions, including ALS. The oral presentations will be led by Dr. Kevin Church and Dr. Hans J. Moebius on April 24 and 25, respectively. A poster presentation on ATH-1105's impact on motor function in an ALS model will occur on April 25. All presentations will be accessible on Athira's website post-event.

Athira Pharma (NASDAQ: ATHA) recently showcased preclinical data at the AD/PD 2023 conference, indicating that fosgonimeton may provide significant neuroprotective, neurotrophic, and anti-inflammatory benefits. Highlights include protection against neurite degeneration and cell death in neuronal cultures, reduced hyperphosphorylated tau levels, and decreased α-synuclein aggregation. The data suggests fosgonimeton could play a role in addressing Alzheimer’s and Parkinson’s diseases. Athira focuses on developing small molecules to restore neuronal health and progress its pipeline targeting the HGF/MET neurotrophic system.

Athira Pharma, Inc. (NASDAQ: ATHA) reported its financial results for the year ending December 31, 2022. The company is advancing its Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease, aiming for enrollment completion by mid-2023 and topline data in early 2024. Athira also progresses with ATH-1105 for ALS and maintains a robust balance sheet with $245.2 million in cash, down from $319.7 million in 2021. The net loss for 2022 was $95.6 million, or $2.53 per share, compared to a loss of $54.9 million, or $1.49 per share, in 2021. Increased operational costs were noted in R&D and G&A expenses.

Athira Pharma (NASDAQ: ATHA) is set to showcase its innovative small molecule therapeutics aimed at enhancing the HGF/MET system for treating various neurodegenerative diseases.

On March 15, 2023, Athira's management will participate in the Needham Neurosciences Investor Forum, followed by the Stifel 2023 CNS Days on March 28-29, 2023. Investors can access live webcasts of the presentations on Athira's website.

Focused on restoring neuronal health, Athira is advancing treatments for Alzheimer's and Parkinson's diseases, among others. The company emphasizes its commitment to developing effective therapies.